Abstract
Abstract
Objectives
Juvenile idiopathic arthritis (JIA) is the most common type of arthritis among children. It can cause joint pain and permanent physical damage, which affects mobility and daily activities. The EQ-5D-Y-3L self-report version has been validated in JIA, but the validity of EQ-5D-Y-5L remains unknown. We examined the psychometric properties of the EQ-5D-Y-5L parent-proxy version among children with JIA.
Methods
We used data from the Understanding Childhood Arthritis Network Canadian-Dutch collaboration study cohort, including patients with new-onset JIA, and those starting or stopping biologics. Clinical data and the parent-proxy version of the childhood health assessment questionnaire (CHAQ) and EQ-5D-Y-5L were collected. We evaluated the ceiling and floor effect; convergent and divergent validity using Spearman’s rank correlation; known-group validity using one-way ANOVA (Analysis of Variance) and effect size; and informativity using Shannon’s evenness index.
Results
467 patient visits representing 407 patients were analyzed. The EQ-5D-Y-5L had no ceiling/floor effect. The EQ-5D-Y-5L showed good convergent (e.g., EQ-5D-Y-5L pain/discomfort dimension vs. CHAQ pain index (Spearman’s r = 0.74, 95% confidence interval (C.I.): 0.69–0.79)), divergent (e.g., EQ-5D-Y-5L pain/discomfort dimension vs. CHAQ eating dimension (Spearman’s r = 0.19, 95% C.I.: 0.09–0.29)) and known-group validity (e.g., mean EQ-5D-Y-5L level summary score for patients with inactive versus active disease status, 6.34 vs. 10.52 (p < 0.001, effect size = 1.20 (95% C.I.: 0.95–1.45)). Shannon’s evenness index ranged from 0.52 to 0.88, suggesting most dimensions had relatively even distributions.
Conclusions
In this patient sample, EQ-5D-Y-5L parent-proxy version exhibited construct validity and informativity, suggesting the EQ-5D-Y-5L can be used to measure the quality of life of children with JIA.
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. Prakken, B., Albani, S., & Martini, A. (2011). Juvenile idiopathic arthritis. The Lancet, 377(9783), 2138–2149. https://doi.org/10.1016/S0140-6736(11)60244-4
2. Ravelli, A., & Martini, A. (2007). Juvenile idiopathic arthritis. The Lancet, 369(9563), 767–778. https://doi.org/10.1016/S0140-6736(07)60363-8
3. Public Health Agency of Canada (2020). Juvenile idiopathic arthritis in Canada. research. Retrieved January 20, 2023, from https://www.canada.ca/en/public-health/services/publications/diseases-conditions/juvenile-idiopathic-arthritis.html
4. Prince, F. H. M., Otten, M. H., & van Suijlekom-Smit, L. W. A. (2010). Diagnosis and management of juvenile idiopathic arthritis. Bmj, 341, c6434. https://doi.org/10.1136/bmj.c6434
5. Gowdie, P. J., & Shirley, M. L. (2012). Juvenile idiopathic arthritis. Pediatric Clinics, 59(2), 301–327.